Supernus Pharmaceuticals, Inc. (SUPN)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). The investigation concerns whether Supernus and certain of its officers and/or directors have violated federal securities laws.


On November 9, 2020, post-market, Supernus disclosed receipt of a complete response letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its new drug application (“NDA”) for SPN-812 for the treatment of ADHD in pediatric patients aged 6-17 years old.  Specifically, the FDA’s CRL “indicate[d] that the review cycle for the application is complete and that the application is not ready for approval in its present form,” and that “[t]he primary issue cited in the SPN-812 CRL relates to the Company’s in-house laboratory that conducts analytical testing, which recently moved to a new location.”  On this news, Supernus’s stock price fell $3.88 per share, or 15.53%, to close at $21.08 per share on November 10, 2020.


If you are aware of any facts relating to this investigation, or purchased Supernus shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.